BINOSTO™ - First and Only Buffered Effervescent Solution for the Treatment of Osteoporosis Launched in the USA

BINOSTO™ - First and Only Buffered Effervescent Solution for the Treatment of Osteoporosis Launched in the USA PR Newswire FREIENBACH, Switzerland, October 23, 2012 FREIENBACH, Switzerland, October 23, 2012 /PRNewswire/ -- EffRx to Regain Rights Outside of North America EffRx Pharmaceuticals SA is proud to announce that BINOSTO™(alendronate sodium) Effervescent Tablet for buffered oral solution (70 mg) is now available by prescription in the United States. The U.S. Food and Drug Administration earlier this year approved BINOSTOto treat osteoporosis in postmenopausal women and to increase bone mass in men with osteoporosis. BINOSTOdelivers the "gold standard" in osteoporosis treatment and fracture risk reduction - alendronate sodium - in an easy-to-swallow, buffered solution. BINOSTO represents a true breakthrough in the treatment of osteoporosis - especially for those patients who prefer not to swallow tablets, or have difficulties swallowing pills. "We are extremely proud having our first product, BINOSTO, launched in the United States by our distribution partner Mission Pharmacal," said Christer Rosén, Chairman and CEO of EffRx. "We are stepping into a new business phase and it is very encouraging to get the news from Mission about the positive reaction BINOSTO has received from the healthcare community in the United States.